Nicolet Advisory Services LLC Has $861,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Nicolet Advisory Services LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 20.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,235 shares of the biopharmaceutical company’s stock after selling 8,263 shares during the quarter. Nicolet Advisory Services LLC’s holdings in Pfizer were worth $861,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer during the fourth quarter worth about $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer in the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $28,000. Noble Wealth Management PBC bought a new position in shares of Pfizer during the fourth quarter worth approximately $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer in the fourth quarter valued at approximately $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Down 1.6 %

Shares of NYSE PFE opened at $24.30 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $137.79 billion, a PE ratio of 17.23, a P/E/G ratio of 0.64 and a beta of 0.61. The company’s fifty day simple moving average is $25.93 and its 200 day simple moving average is $26.81. Pfizer Inc. has a 12-month low of $24.26 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the business posted $0.10 EPS. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.